Profile of several autoantibodies, complement and vitamin D levels in Brazilian patients with Chikungunya infection

Cover Page

Cite item


Introduction. Chikungunya virus infection (CKV) may lead to chronic arthritis in up to 40% of the patients. There are previous data regarding positive auto antibodies in CKV. Objective is to systematically evaluate the prevalence of auto antibodies in CKV patients. Methods. All study participants had clinical manifestations being CKV positive at least serologally or by RT-PCR data. The following autoantibodies were assessed: antinuclear antibodies (ANA), anti-dsDNA, anti-Sm, anti-Ro/SS-A, anti-La/SS-B, anti-U1RNP, IgG and IgM anticardiolipin, anticyclic citrullinated peptide (antiCCP), rheumatoid factor (RF), antiribosomal P protein, lupus anticoagulant, anti-Jo-1 and anti-Scl-70. CH100, C3 and C4 complement components, serum levels of immunoglobulins, C-reactive protein, erythrocyte sedimentation rate, alpha1-acid glycoprotein, antithyroglobulin, antithyroperoxidase, TRAb, 25 hydroxyvitamin D (25OHD), dengue and zika IgG and IgM antibodies were also measured. Results. 30 CKV patients were included. Mean age was 59.1±15.7 years, 85% females and 77% Caucasian subjects. Disease duration comprised 4.9±4.0 months. Oligoarthritis was observed in 93% cases. Mean C-reactive protein levels were 10.1±6.8 ng/dL, erythrocyte sedimentation rate — 34.2±19.9 mm/1st hour and alpha1-acid glycoprotein 115.5±52.6 mg/dL. Intramuscular betamethasone depot single dose injection was administered in 54%, prednisone — in 15% and methotrexate — in 23% cases. Importantly, 1/30 (3.3%) cases was positive for ANA, 4/30 (13.3%) — for RF and none was positive for anti-CCP or any other autoantibodies. Complement and immunoglobulin levels were all within the normal range. Low levels of 25OHD were observed in 88% cases.

About the authors

J. F. Carvalho

Federal University of Bahia

Author for correspondence.
ORCID iD: 0000-0002-7957-0844

Jozélio Freire Carvalho,  MD, PhD, Institute for Health Sciences 



L. R. Cordeiro

Federal University of Bahia


Graduate Student, Bahian School of Medicine and Public Health 



F. F. Silva

University of São Paulo


MD, Doctoral Student, Clinics Hospital of Faculty of Medicine 

São Paulo


L. Mota

University of Brasilia


MD, PhD, Assistant Professor, Rheumatology Service, University Hospital of Brasilia 



C. Rodrigues

University of Fortaleza


MD, PhD, Assistant Professor 



C. F. Andrade

National School of Public Health Sérgio Arouca; Vassouras University


MD, DSc, Assistant Professor, Department of Epidemiology and Quantitative Methods in Health; Faculty of Medicine 

Rio de Janeiro


C. Caldas

Federal University of Pará


MD, PhD, Assistant Professor, Faculty of Medicine, Tropical Medicine Center 




  1. Blettery M., Brunier L., Polomat K., Moinet F., Deligny C., Arfi S., Jean-Baptiste G., De Bandt M. Brief report: management of chronic post-Chikungunya rheumatic disease: the martinican experience. Arthritis Rheumatol., 2016, vol. 68, no. 11, pp. 2817– 2824. doi: 10.1002/art.39775
  2. Bouquillard E., Combe B. A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years. Joint Bone Spine, 2009, vol. 76, no. 6, pp. 654–657. doi: 10.1016/j.jbspin.2009.08.005
  3. Chang A.Y., Martins K.A.O., Encinales L., Reid S.P., Acuña M., Encinales C., Matranga C.B., Pacheco N., Cure C., Shukla B., Ruiz Arteta T., Amdur R., Cazares L.H., Gregory M., Ward M.D., Porras A., Rico Mendoza A., Dong L., Kenny T., Brueggemann E., Downey L.G., Kamalapathy P., Lichtenberger P., Falls O., Simon G.L., Bethony J.M., Firestein G.S. Chikun gunya arthritis mechanisms in the Americas: a cross-sectional analysis of Chikungunya arthritis patients twenty-two months after infection demonstrating no detectable viral persistence in synovial fluid. Arthritis Rheumatol., 2018, vol. 70, no. 4, pp. 585–593. doi: 10.1002/art.40383
  4. Faria N.R., Lourenco J., Cerqueira E.M., Lima M.M., Pybus O., Alcantara L.C.J. Epidemiology of Chikungunya virus in Bahia, Brazil, 2014–2015. PLoS Curr., 2016, vol. 8: ecurrents.outbreaks.c97507e3e48efb946401755d468c28b2. doi: 10.1371/currents.outbreaks.c97507e3e48efb946401755d468c28b2
  5. Gualberto Cavalcanti N., Melo Vilar K., Branco Pinto Duarte A.L., Barreto de Melo Rêgo M.J., Pereira M.C., da Rocha Pitta I., Diniz Lopes Marques C., Galdino da Rocha Pitta M. Increased serum levels of galectin-9 in patients with chikungunya fever. Virus Res., 2020, vol. 286: 198062. doi: 10.1016/j.virusres.2020.198062
  6. Inamadar A.C., Palit A., Sampagavi V.V., Raghunath S., Deshmukh N.S. Cutaneous manifestations of chikungunya fever: observations made during a recent outbreak in south India. Int. J. Dermatol., 2008, vol. 47, no. 2, pp. 154–159. doi: 10.1111/j.1365- 4632.2008.03478.x
  7. Javelle E., Ribera A., Degasne I., Gaüzère B.A., Marimoutou C., Simon F. Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006–2012. PLoS Negl. Trop. Dis., 2015, vol. 9, no. 3: e0003603. doi: 10.1371/journal.pntd.0003603
  8. Manimunda S.P., Vijayachari P., Uppoor R., Sugunan A.P., Singh S.S., Rai S.K., Sudeep A.B., Muruganandam N., Chaitanya I.K., Guruprasad D.R. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans. R. Soc. Trop. Med. Hyg., 2010, vol. 104, no. 6, pp. 392–399.
  9. Marques C.D.L., Duarte A.L.B.P., Ranzolin A., Dantas A.T., Cavalcanti N.G., Gonçalves R.S.G., Rocha Junior L.F.D., Valadares L.D.A., Melo A.K.G., Freire E.A.M., Teixeira R., Bezerra Neto F.A., Medeiros M.M.D.C., Carvalho J.F., Santos M.S.F., Océa R.A.L.C., Levy R.A., Andrade C.A.F., Pinheiro G.D.R.C., Abreu M.M., Verztman J.F., Merenlender S., Ribeiro S.L.E., Costa I.P.D., Pileggi G., Trevisani V.F.M., Lopes M.I.B., Brito C., Figueiredo E., Queiroga F., Feitosa T., Tenório A.D.S., Siqueira G.R., Paiva R., Vasconcelos J.T.S., Christopoulos G. Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 — Diagnosis and special situations. Rev. Bras. Reumatol., 2017, vol. 57, pp. 421–437. doi: 10.1016/j.rbre.2017.05.006
  10. Miner J.J., Yeang H.X.A., Fox J.M., Taffner S., Malkova O.N., Oh S.T., Kim A.H.J., Diamond M.S., Lenschow D.J., Yokoyama W.M. Brief report: chikungunya viral arthritis in the United States: a mimic of seronegative rheumatoid arthritis. Arthritis Rheumatol., 2015, vol. 67, no. 5, pp. 1214–1220. doi: 10.1002/art.39027
  11. Pereira A.B.C., Albuquerque L.C.F., Souza R.C.M., Carvalho J.F., Caldas C.A.M. Musculoskeletal manifestations observed in patients diagnosed with Chikungunya virus in 2 municipalities of the Brazilian Amazon Region. J. Clin. Rheumatol., 2020, vol. 26, no. 7S, suppl. 2, pp. S195–S198. doi: 10.1097/RHU.0000000000001366
  12. Rulli N.E., Melton J., Wilmes A., Ewart G., Mahalingam S. The molecular and cellular aspects of arthritis due to alphavirus infections: lesson learned from Ross River virus. Ann. NY Acad. Sci., 2007, vol. 1102, pp. 96–108. doi: 10.1196/annals.1408.007
  13. Tanay A. Chikungunya virus and autoimmunity. Curr. Opin. Rheumatol., 2017, vol. 29, no. 4, pp. 389–393. doi: 10.1097/BOR.0000000000000396
  14. Wahid B., Ali A., Rafique S., Idrees M. Global expansion of chikungunya virus: mapping the 64-year history. Int. J. Infect. Dis., 2017, vol. 58, pp. 69–76. doi: 10.1016/j.ijid.2017.03.006

Supplementary files

There are no supplementary files to display.

Copyright (c) 2021 Carvalho J.F., Cordeiro L.R., Silva F.F., Mota L., Rodrigues C., Andrade C.F., Caldas C.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies